Medical Writing in Clinical Trials

Medical writing in clinical trials is the specialized function of drafting and maintaining the regulatory and clinical documents a trial requires — protocols, Investigator’s Brochures, informed consent forms, Clinical Study Reports, the clinical sections of regulatory submissions, and trial-related publications — to the structural and ethical standards those document types demand. On larger trials and at sponsor/CRO organizations, this work is typically performed by dedicated medical writers; on smaller or investigator-initiated trials, the same document-drafting responsibilities are often absorbed by the principal investigator, a Clinical Research Associate, or regulatory staff, without a dedicated writer role existing at all.

What medical writers produce

The discipline spans several distinct document families, each with its own standard and audience:

• Protocols and protocol amendments — the operational and scientific plan for the trial, structured per ICH E6 (Good Clinical Practice) expectations for content and organization.
• Investigator’s Brochures (IB) — the compiled clinical and nonclinical data on an investigational product, given to investigators and ethics committees so they can assess the risk/benefit basis for the trial; also structured per ICH GCP guidance.
• Informed consent forms (ICF) — participant-facing documents that must accurately reflect the protocol while meeting IRB/ethics-committee readability and comprehension standards. See CASRAI’s Informed Consent entry and Informed Consent in Research guide for the ethical and regulatory framework itself; medical writing is the document-drafting function that produces compliant ICF language, not the ethics review process.
• Clinical Study Reports (CSRs) — the comprehensive report of a completed trial’s methods, results, and conclusions, structured to the 16-section outline defined in ICH E3. CSR authorship is one of the most standardized and document-heavy parts of the discipline.
• Clinical sections of regulatory submissions — the clinical overview, clinical summary, and study-report modules assembled into a marketing-authorization application (e.g. Common Technical Document Module 2 and Module 5 content) for FDA, EMA, or other regulators.
• Publication-related writing — manuscripts, congress abstracts, posters, and increasingly plain-language summaries of trial results for lay audiences, produced under Good Publication Practice guidance (below) and standard authorship criteria such as ICMJE’s.

Standards and guidance the discipline works to

Medical writing is document-standard-driven rather than freeform technical writing. The main reference points are:

• ICH E3 (“Structure and Content of Clinical Study Reports”) — the primary standard for CSR structure; see CASRAI’s dedicated Clinical Study Report (CSR) entry for the full section-by-section breakdown.
• ICH E6 (Good Clinical Practice) — governs protocol content and conduct expectations that protocol and consent-form writing must reflect; see CASRAI’s ICH E6(R3) entry.
• Good Publication Practice (GPP) — the guideline specifically covering company-sponsored biomedical research publications, including the role and disclosure of professional medical writers. The current version, published in the Annals of Internal Medicine in August 2022, is referred to as GPP 2022 rather than “GPP3” — the update deliberately dropped version numbering in favor of naming updates by year, so GPP 2022 supersedes the earlier GPP3 (2015) as the current guidance; a GPP4 update was reported to be in development as of this writing but had not been published. GPP 2022 requires that named authors retain control of content and interpretation, that medical writing support and its funding source be disclosed, and that authorship follow recognized criteria such as ICMJE’s.
• European Medical Writers Association (EMWA) — the primary professional body for medical writers in Europe, publishing competency frameworks and guidance the discipline widely references for training and professional standards; the American Medical Writers Association (AMWA) plays an equivalent role in North America.

Medical writer vs. Regulatory Affairs professional vs. general clinical documentation

These roles are frequently confused because they overlap on the same documents, but they are distinct functions:

• Medical writer: owns the drafting, structuring, and document-lifecycle management of clinical and regulatory content to the applicable standard (ICH E3, GPP 2022, etc.). Does not typically decide regulatory strategy or represent the sponsor before an agency.
• Regulatory affairs professional (e.g. a Regulatory Affairs Certification, RAC, holder): owns the regulatory strategy, agency interactions, and overall submission planning and compliance — deciding what needs to be submitted, when, and through which pathway. A RAC credential certifies competency in regulatory strategy and process, not document drafting; regulatory affairs staff frequently rely on medical writers to produce the clinical narrative content that goes into the submissions they manage.
• General clinical documentation (source documents, CRFs, monitoring visit reports, site correspondence): produced by site staff, CRAs, or data management as part of routine trial conduct and oversight. These are operational records, not the structured, standard-driven narrative deliverables medical writing produces from that underlying data.

In practice the three functions collaborate closely — the medical writer depends on data and interpretation supplied by the clinical/biostatistics team, structures it to the correct regulatory or publication standard, and hands the finished document to regulatory affairs for submission or to the named authors for journal submission.

Related terms

• Clinical Study Report (CSR)
• ICH E6(R3)
• Informed Consent
• Clinical Research Associate (CRA)
• Principal Investigator (PI)

Note: this entry describes the medical writing discipline, its standard document types, and the guidance that governs them. It does not reproduce or model the actual content of a CSR, protocol, or IB — see the dedicated Clinical Study Report (CSR) entry for that document’s structure specifically.